KCSA Strategic Communications Wins Coveted PRNEWS Platinum Award for Maps’ Psychedelic Science 2023 Conference
October 10, 2024 16:06 ET
|
KCSA Strategic Communications
KCSA Strategic Communications wins the PRNEWS Platinum Award for “Best Conference Marketing/PR Campaign” for Psychedelic Science 2023 (PS2023) Conference
PharmAla to supply the University of Texas, San Antonio, with novel dosage form of LaNeo™ MDMA
October 08, 2024 08:55 ET
|
PharmAla Biotech
PharmAla signs contract to develop novel dosage form of LaNeo MDMA, to be used in clinical trial at University of Texas San Antonio
PharmAla to supply Harvard Medical School’s Maclean Hospital with LaNeo MDMA
October 02, 2024 09:20 ET
|
PharmAla Biotech
PharmAla Biotech signs contract to supply Harvard neuropsychiatry hospital with MDMA; Appears at CPHI Conference in Milan
Japan Major Depressive Disorder (MDD) Market Forecast and Opportunities 2020-2030: Increasing Awareness and Decreasing Stigma of Mental Health Disorders
September 16, 2024 06:15 ET
|
Research and Markets
Dublin, Sept. 16, 2024 (GLOBE NEWSWIRE) -- The "Japan Major Depressive Disorder (MDD) Market, By Region, Competition, Forecast and Opportunities, 2020-2030F" report has been added to ...
Psychedelic Therapeutics Clinical Trials Research Report 2024 Featuring Yale University, Johnson & Johnson, Shire Pharmaceuticals, Pfizer, Lykos, and UCB
September 13, 2024 06:55 ET
|
Research and Markets
Dublin, Sept. 13, 2024 (GLOBE NEWSWIRE) -- The "Clinical Trials: Psychedelic Therapeutics" report has been added to ResearchAndMarkets.com's offering.This report provides a review of global...
PharmAla to supply Johns Hopkins Medicine for Clinical Trial
September 11, 2024 08:55 ET
|
PharmAla Biotech
PharmAla completes sales agreement with Johns Hopkins Medicine, terminates contract with Red Light Holland, to present novel molecule at conference.
PharmAla Launches MDMA Clinical Trial Tool for Researchers
August 22, 2024 09:07 ET
|
PharmAla Biotech
PharmAla announces the launching of a new tool for clinical researchers, and the appointment of a new CFO effective Oct. 1
atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)
August 13, 2024 07:00 ET
|
atai Life Sciences
VLS-01 demonstrated a good safety and tolerability profile and a short psychedelic experience, enabling a total in-clinic treatment of two hours.
MAPS Statement on FDA Complete Response Letter for MDMA-Assisted Therapy for PTSD New Drug Application
August 09, 2024 21:33 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
MAPS remains confident in its goal of making access to MDMA-assisted therapy for PTSD safe and legal SAN JOSE, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for...
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
August 09, 2024 18:18 ET
|
PharmAla Biotech
PharmAla expresses disappointment in USFDA's decision to request a third Phase 3 for MDMA and announces the patent granting for a safer MDMA analog variant